June 2026– date –
-
A Quarter of Enterprise AI Agent Deployments Fail ROI Targets, Citing Governance and IAM Deficiencies
ITSM.tools 他 UK Overview New 2026 research indicates that 25% of AI agent deployments in large UK enterprises are failing to achieve their expected ROI, primarily due to critical governance gaps. Key challenges include the absence of pu... -
FDA-Cleared AI “Artera AI Breast” Demonstrates Clinical Utility for Breast Cancer Prognosis and Chemotherapy Benefit Prediction at ASCO 2026
The Pathologist USA Overview At ASCO 2026, a study showcased the utility of Artera AI Breast, an FDA-cleared multimodal artificial intelligence model, for predicting prognosis and chemotherapy benefit in postmenopausal women with node-po... -
OpenAI, Anthropic, Microsoft CEOs Call for Stricter Laws Against AI Biothreats to Synthetic DNA/RNA
Financial Express USA Overview CEOs from OpenAI, Anthropic, and Microsoft AI, alongside over 50 other signatories, have pressed the US Congress to implement more stringent regulations on synthetic DNA and RNA to mitigate AI-enabled bioth... -
AI/ML Transforms Drug Discovery, Boosting Efficiency and Precision from Target to Clinic
PubMed Central (Preprints経由) International Overview A recent review underscores the transformative impact of AI and Machine Learning (AI/ML) across the entire drug discovery pipeline, from initial target identification to clinical tria... -
ImmunoFoundation: Novel Multimodal Foundation Model for Immunogenicity Prediction and Peptide Optimization Overcomes Data Scarcity
OpenReview USA Overview Researchers have introduced ImmunoFoundation, a self-supervised multimodal foundation model designed for immunogenicity prediction and peptide optimization. By integrating an ESM-2 sequence encoder with a graph tr...
